2-溴-5-羟基甲基苯甲醚 | 17100-64-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-5-羟基甲基苯甲醚
• 中文别名: 2-溴-5-羟甲基-苯甲醚；4-溴-3-甲氧基苄醇
• 英文名称: (4-bromo-3-methoxyphenyl)methanol
• 英文别名: 4-bromo-3-methoxybenzyl alcohol
• CAS: 17100-64-0
• 化学式: C₈H₉BrO₂
• 分子量: 217.062
• InChiKey: KXUYHKRDJBTPDF-UHFFFAOYSA-N

物化性质

• 沸点：
  306.8±27.0 °C(Predicted)
• 密度：
  1.513±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2909499000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放于室温、干燥处，并密封保存。

反应信息

• 作为反应物：
  描述：

  2-溴-5-羟基甲基苯甲醚 在 盐酸 、 四(三苯基膦)钯 、 正丁基锂 、 18-冠醚-6 、 四溴化碳 、 5%-palladium/activated carbon 、 水 、 氢气 、 sodium methylate 、 三溴化硼 、 sodium carbonate 、 potassium carbonate 、 对甲苯磺酸 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 甲苯 为溶剂， -40.0~25.0 ℃ 、300.01 kPa 条件下， 反应 145.0h， 生成 4-[(Dimethylamino)methyl]-14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2(7),3,5,10(29),11,13(28),15,17,19(27),22,25-dodecaene-3,16,24-triol
  参考文献：
  名称：

  Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents

  摘要：

  Based on the core skeleton of the total synthesized bisbibenzyl marchantin C, riccardin D and plagiochin E, a series of brominated and aminomethylated derivatives of above three bisbibenzyls have been synthesized and their cytotoxic activity against KB, MCF-7 and PC3 cell lines has been preliminary evaluated. The bio-test results revealed that the brominated derivatives 21, 22, 24, 25 and 28 exhibited excellent antiproliferative activity, with IC50 value lower than their parent compounds. As a most potent microtubule depolymerization agent, compound 28 was found to arrest cells at the G(2)/M phase of the cell cycle as determined by the flow cytometry assay in PC3 cell line. The remarkable biological profile and novel structure of these bisbibenzyl derivatives make them possible as promising candidates for clinical development as chemotherapeutic agents. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.02.004
• 作为产物：
  描述：

  间甲氧基苯甲醇 在 N-溴代丁二酰亚胺(NBS) 、 水 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以97%的产率得到2-溴-5-羟基甲基苯甲醚
  参考文献：
  名称：

  N-溴代琥珀酰亚胺：一种用于将苯甲醇氧化成醛的简便试剂

  摘要：

  摘要 已经描述了在环境条件下使用 N-溴代琥珀酰亚胺 (NBS) 在不使用过渡金属催化剂的情况下将苯甲醇氧化成醛。

  DOI：

  10.1080/00397910701239023

文献信息

• 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
  申请人：Sekiguchi Yoshinori

  公开号：US20080318923A1

  公开（公告）日：2008-12-25

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  旨在提供一种对与精氨酸加压素V1b受体相关的病理状况具有疗效的药物。更具体地说，旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫疾病、脱发等具有治疗或预防作用的药物。经过深入研究，发现了一种新颖的1,3-二氢-2H-吲哚-2-酮化合物和与杂芳环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性，表现出有利的血脑屏障穿透和高血浆浓度，从而实现了上述目标。
• FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF
  申请人：GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.

  公开号：US20180208604A1

  公开（公告）日：2018-07-26

  Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

  揭示的区域融合环嘧啶化合物，以及中间体、制备方法、组合物及其用途。融合环嘧啶化合物是如下式I所示的化合物，其为互变异构体、对映异构体、顺反异构体、药学上可接受的盐、代谢物、代谢前体或其前药，上述化合物用于制备用于预防、缓解或治疗免疫系统疾病、自身免疫疾病、细胞增殖性疾病、过敏性疾病和心血管疾病中的一种或多种的药物，且该化合物对Janues激酶、FGFR激酶、FLT3激酶和Src家族激酶具有强烈的抑制作用。
• SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES
  申请人：Bouey Edith

  公开号：US20100004159A1

  公开（公告）日：2010-01-07

  The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

  本发明涉及多取代咪唑酮衍生物，包括它们的药物组合物以及在人类和动物健康领域中的治疗用途。本发明还涉及一种制备这些衍生物的方法。
• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
  申请人：Novartis AG

  公开号：US20210115065A1

  公开（公告）日：2021-04-22

  The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.

  本发明提供了化合物(Ia)的结构或其药学上可接受的盐； 一种制造本发明化合物的方法，固体形式，药理活性剂的组合，药物组合物以及使用这些化合物和固体形式来治疗或预防寄生虫病，例如疟疾的方法。
• [EN] COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS ET PROCÉDÉS D'UTILISATION DESDITS COMPOSÉS
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2018098499A1

  公开（公告）日：2018-05-31

  The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

  本发明部分涉及融合的杂环化合物和组合物，用于预防和/或治疗与电压门控钠离子通道异常功能相关的疾病或症状，例如异常的晚期/持续性钠电流。本文还提供了治疗与钠离子通道异常功能相关的疾病或症状，包括德拉维特综合征或癫痫的方法。